Systematic Review ARTICLE
The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-analysis
- 1Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, China
- 2The Second School of Clinical Medicine, Southern Medical University, China
- 3The First School of Clinical Medicine, Southern Medical University, China
- 4The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, China
Background: Although gemcitabine plus cisplatin (GP) is considered as standard chemotherapy for patients with advanced biliary tract cancer (BTC), the optimal regimen remains unknown.
Methods: Using Network meta-analysis (NMA), a systematic review was conducted to find the most effective chemotherapy regimen for advanced BTC. We searched PubMed, Web of Science, Embase, Scopus and the Cochrane Library for articles published before October 6, 2018. Articles about chemotherapeutic comparisons were included. Hazard ratios (HRs) for overall survival (OS) and progression free survival (PFS) were estimated while odd ratios (ORs) was assessed for objective response rate (ORR).
Results: The NMA included 25 studies and 3,312 individuals. Among all the regimens, Folfox-4 regimen obtained a superior difference in OS (BSC vs. Folfox-4, HR 3.4, 95% CI 1.7-6.7). XP was slightly better than GP in OS and GS approximately obtained the same efficacy to GP (HR for XP vs. GP 0.74, 95% CI 0.51-1.1; HR for GS vs. GP 1.1, 95% CI 0.71-1.5). Most of the targeted therapies included in this study tend to achieve better in PFS and ORR but failed to improve OS, in which E-GEMOX achieved the best ORR when compared to BSC (OR 0.03, 95% CI 0.00-0.94).
Conclusions: Folfox-4 regimen is likely to be the optimal chemotherapy for patients with advanced BTC and the predominant targeted therapy haven’t achieved significant success currently. XP and GS can be considered as alternatives for advanced BTC.
Keywords: Biliary tract cancer, chemotherapy, FOLFOX-4, Network meta-analysis, efficacy
Received: 21 Feb 2019;
Accepted: 09 May 2019.
Edited by:Tzi Bun Ng, The Chinese University of Hong Kong, China
Reviewed by:Hu Liu, Anhui Provincial Cancer Hospital, China
Weicheng Liang, Sun Yat-sen University, China
Copyright: © 2019 Li, Zhou, Hong, He, Wei, Yang, Zheng and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
MD, PhD. Da y. Zheng, Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, China, firstname.lastname@example.org
MD, PhD. Fei y. Liu, Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, China, email@example.com